Tuyen Ong

Dr. Ong is a Physician, Bioentrepreneur and Ring’s CEO. Prior to joining Ring Therapeutics, Dr. Ong served as Senior Vice President at Biogen. Previously, Dr. Ong served as chief development officer at Nightstar Therapeutics up until its acquisition by Biogen. During this time, he was involved with the company’s public listing on the NASDAQ, corporate and gene therapy strategy, investor and M&A activities. Dr. Ong brings over 20 years of clinical and drug development experience from both large pharma and biotech, working in the fields of genetic, ophthalmology, and rare disease at PTC Therapeutics Inc., Bausch and Lomb Inc. (acquired by Valeant Pharmaceuticals International, Inc.), and Pfizer.

Dr. Ong holds an M.D. from the University College London and an M.B.A. from New York University Stern School of Business. He is a member of the Royal College of Ophthalmologists and a Churchill Fellow.